Shanghai Dahua Pharmaceutical Co.

What Shanghai Dahua Pharmaceutical Co. does

Shanghai Dahua Pharmaceutical Co., Ltd. is a privately held Chinese pharmaceutical manufacturer founded in 1991 and headquartered at 3503 Changzheng Road, Changzheng Farm, Chongming County, Shanghai. The company specializes in the production of long-acting reversible contraceptive (LARC) implants, with a single core product line: Sino-implant (II), sold internationally under the brand Levoplant. The product is a subdermal contraceptive implant consisting of two thin, flexible silicone rods, each containing 75 mg of levonorgestrel (150 mg total), delivered with a CE-marked disposable trocar and providing multi-year reversible contraception following a single insertion procedure.

The company is registered as a private limited company under the laws of Shanghai, China, and operates with a small employee base of 11-50 people. Its product is registered in over 40 countries worldwide and is procured primarily through public-sector channels — UN agencies, ministries of health, and international family planning programs — enabled in part by WHO prequalification obtained on June 30, 2017. Distribution is handled via a B2B model with a dedicated distribution inquiry contact ([email protected]), and the company supports buyers with downloadable training resources, reference guides, pharmacovigilance forms, and product brochures targeted at healthcare providers.

Dahua's business model is centered on one-time product sales of a single high-volume, low-unit-cost contraceptive implant into global public health procurement channels. Revenue mechanics are not publicly disclosed, and no pricing, revenue figures, funding rounds, ownership structure, or management team details are available in the source material. The company's stated mission is to provide quality, safe, effective, and affordable reproductive health solutions for women globally, with values centered on integrity, quality, and collaboration.

Name

Shanghai Dahua Pharmaceutical Co.

Legal name

Shanghai Dahua Pharmaceutical Co., Ltd.

Website

https://dahua-sh.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

11–50 employees

Short description

Shanghai Dahua Pharmaceutical Co., Ltd. is a privately held Chinese pharmaceutical manufacturer founded in 1991 that produces Levoplant (Sino-implant II), a two-rod levonorgestrel subdermal contraceptive implant registered in 40+ countries and procured by global health programs.

Ownership category

akta.pro rank

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Contraceptive Implant Product Sales: Direct product sales of Sino-implant (II)/Levoplant contraceptive implants to healthcare providers, governments, and distributors globally. The company produces and sells long-acting reversible contraceptive (LARC) implants.

Distribution channels1 record

Marketing channels2 records

Core offering

Shanghai Dahua Pharmaceutical Co., Ltd. manufactures and sells Levoplant (Sino-implant II), a subdermal contraceptive implant composed of two thin, flexible silicone rods, each containing 75 mg levonorgestrel for a total of 150 mg. The product provides long-acting reversible contraception for up to several years and is delivered with a CE-marked disposable trocar. It is registered in over 40 countries worldwide and serves governments, healthcare providers, and international family planning programs.

Product overview

Shanghai Dahua Pharmaceutical Co. is a pharmaceutical manufacturer specializing in long-acting reversible contraceptive implants. The company offers a single core product line consisting of Levoplant (also known as Sino-implant II), a two-rod subdermal contraceptive implant containing 150 mg of levonorgestrel total. The product is a high-quality, CE-marked device sold with a disposable trocar and is registered in over 40 countries worldwide. The portfolio centers entirely on this contraceptive implant offering.

Differentiator

Problem solved

Functional benefit

Brands

• Levoplant: A high-quality two-rod contraceptive implant sold globally, also known as Sino-implant (II). It is a subdermal contraceptive implant composed of two thin, flexible, silicone rods, each containing 75 mg levonorgestrel, for a total of 150 mg.
• Sino-implant (II)

Products and services

• Levoplant (Sino-implant II) A subdermal contraceptive implant composed of two thin, flexible silicone rods, each containing 75 mg levonorgestrel for a total of 150 mg. Provides long-acting reversible contraception for up to several years. Sold under the global brand Levoplant and registered in over 40 countries worldwide. Delivered with a CE-marked disposable trocar. Targeted at governments, healthcare providers, and international family planning programs procuring contraceptives for women of reproductive age.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Broad incumbents

• Cipla: Indian pharmaceutical major with a women's health portfolio across hormonal contraceptives and reproductive health. Comparable as a broad incumbent in the same therapeutic and emerging-market channels.
• Teva Pharmaceutical Industries: Global pharmaceutical manufacturer with women's health generics including oral contraceptives and hormonal therapies. Comparable as a broad incumbent serving overlapping therapeutic categories.
• Viatris (formerly Mylan): Global generic and women's health pharmaceutical manufacturer with historical presence in hormonal contraceptives and reproductive health generics. Comparable as a broader incumbent in the same therapeutic category.

Direct peers

• Organon & Co. Organon markets Nexplanon/Implanon, the leading single- and now bioequivalent two-rod etonogestrel subdermal contraceptive implant. It is the closest direct competitor to Dahua's Levoplant in the global LARC implant category.
• Bayer: Bayer manufactures Mirena, Kyleena and other hormonal IUDs as well as Jadelle (a two-rod levonorgestrel implant). It is a directly competing long-acting reversible contraceptive manufacturer with overlapping global health distribution.
• DKT International: Large nonprofit distributor and social marketer of contraceptives and reproductive health products across 90+ countries. Comparable as a peer operating in the same global family planning supply and procurement ecosystem.
• Pfizer: Pfizer markets Sayana Press (depot medroxyprogesterone acetate subcutaneous injectable), a competing long-acting hormonal contraceptive widely procured in LMICs, alongside historical implant portfolios.

Emerging players

• Lupin Pharmaceuticals: Indian pharma company with women's health and hormonal contraceptive portfolio serving emerging markets. Comparable as an emerging low-cost supplier in the same therapeutic category.
• WomanCare Global (GHIT/WCG): Reproductive health company focused on expanding access to contraceptive technologies in LMICs. Comparable as a peer operating in the same global access-oriented contraceptive ecosystem.
• Cupid Limited: Indian manufacturer focused on hormonal contraceptive products including implants and injectables. Comparable as an emerging low-cost player in the same global reproductive health procurement channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shanghai Dahua Pharmaceutical Co.